Vascular Dynamics

We are looking forward to attending #HeartFailure2024 this weekend and hope to see you there. We are actively recruiting sites for our MOBIUS-HF clinical trial of the #MobiusHD device for heart failure. Perry Rice, VP of Clinical Affairs, will be in Lisbon and would like to meet. Leave a comment below and we’ll be in touch to schedule a time. See you in Lisbon! #heartfailure, #EVBA, #cardiology #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor, #HFA_ESC

We are looking forward to attending #ACC24 this week and hope to see you there. We are actively recruiting sites for our MOBIUS-HF clinical study of the #MobiusHD device for heart failure. Perry Rice, VP of Clinical Affairs, will be in Atlanta and would like to meet. Contact us directly or leave a comment below and we’ll be in touch to schedule a meeting. See you in Atlanta! #heartfailure, #EVBA, #cardiology, #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor

Today, we are celebrating enrollment of the 50th patient in our #MobiusHD® HF feasibility study. Many thanks to our clinical investigators and research teams for helping us achieve this enrollment milestone. We are pleased with 100% MobiusHD implant success rate with an average procedure time of less than 30 minutes. We are grateful to our partners, SCIRENT Clinical Research and Science and Angio Consult GmbH, for their valuable contributions. We look forward to kicking off our pivotal study in the near future. Note: MobiusHD is an investigational device and not for sale in any geography. #heartfailure, #EVBA, #cardiology #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor

Thanks to #THT2024 and Prof. Dr. Horst Sievert for speaking about endovascular baroreflex amplification with the #MobiusHD device. Key takeaways included significant improvements in KCCQ, 6MWD, LVEF and NT-proBNP levels maintained through 24 months and positive mechanistic indicators, including a durable reduction in heart rate. A larger pivotal study is planned. Contact us to learn more. Note: MobiusHD is an investigational device and not for sale in any geography. #heartfailure, #EVBA, #cardiology #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor

Congratulations to Dr. Dragana Kosevic, Želimir Antonić, Dr. Mihajlo Farkic, and staff at the Institut for Cardiovascular Disease Dedinje, Belgrade and SCIRENT Clinical Research and Science for their first three successful #MobiusHD implants!    MobiusHD® is a novel, investigational device designed to restore baroreceptor sensitivity, amplify the #baroreflexresponse and improve cardiovascular function in symptomatic #heartfailure patients despite optimal drug treatment. Learn more about #MobiusHD and #enrollment in the #clinicalstudy at www.vasculardynamics.com. Mobius HD is an investigational device and not for sale in any geography.  

Don’t miss Prof. Horst Sievert speak about endovascular baroreflex amplification at #THT2024. Tomorrow, he will present updated 24-month results of the #MobiusHD device for patients with #HFrEF. Tuesday at 3:49pm in Grand Ballroom C-E. Neuromodulation for Heart Failure #heartfailure, #EVBA, #cardiology #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor

We are excited to be attending #THT2024 next week in Boston. Visit us at Booth #6 and check out our poster abstract to learn more about the #MobiusHD implant and how it delivers potentially clinically meaningful and durable clinical benefit in #HFrEF. Monday, March 4th Sustained Functional Improvements from Endovascular Baroreflex Amplification (EVBA) in Symptomatic HFrEF. Presenter: JoAnn Lindenfeld #heartfailure, #EVBA, #cardiology #innovationinhealthcare, #healthcareinnovation, #meddevice #medtech, #neuromodulation, #baroreflex, #baroreceptor

The Vascular Dynamics team wishes you a heart healthy 2024! At VDI, we are lighting the way to find new options to treat heart failure in symptomatic patients with reduced ejection fraction (HFrEF). MobiusHD® is a novel, investigational device designed to restore baroreceptor sensitivity, amplify the #baroreflexresponse and improve cardiovascular function in symptomatic #heartfailure patients despite optimal drug treatment. (Mobius HD is an investigational device and not for sale in any geography.)  To learn more, please visit www.vasculardynamics.com #Healthy2024 #MobiusHD

Congratulations to Prof. Dr. Marija Zdravkovic MD, PhD, FESC, Dr. Davor Mrda, Dr. Viseslav Popadic, Dr. Djordje Marinkovic, Dr. Jovana Lalatović and staff at the University Hospital Medical Center Bežanijska Kosa and SCIRENT Clinical Research and Science for the first #MobiusHD implant!  MobiusHD® is a novel, investigational device designed to restore baroreceptor sensitivity, amplify the #baroreflexresponse and improve cardiovascular function in symptomatic #heartfailure patients despite optimal drug treatment. Learn more about  #MobiusHD and #enrollment in the #clinicalstudy at www.vasculardynamics.com (Mobius HD is an investigational device and not for sale in any geography.)

Congratulations to Prof. Dr. med. habil. Linke Axel, Dr. med. Ephraim Winzer and staff at Heart Center University Hospital Dresden for another #MobiusHD implant!  MobiusHD® is a novel, investigational device designed to restore baroreceptor sensitivity, amplify the #baroreflexresponse and improve cardiovascular function in symptomatic #heartfailure patients despite optimal drug treatment. Learn more about #MobiusHD and #enrollment in the #clinicalstudy at www.vasculardynamics.com (Mobius HD is an investigational device and not for sale in any geography.)